Sukeshi Patel Arora Martine Puts Published: May 23, 2023 DOI: https://doi.org/10.1016/j.jgo.2023.101528
Fabio P. Mansani Ruffo Freitas-Junior Published: May 22, 2023 DOI:https://doi.org/10.1016/j.jgo.2023.101526
Sébastien Gendarme Sonia Zebachi Romain Corre Laurent Greillier Grégoire Justeau Olivier Bylicki Chantal Decroisette Jean-Bernard Auliac Florian Guisier Margaux Geier Charles Ricordel Maxime Frelaut Elena Paillaud Christos Chouaïd Florence Canouï-Poitrine Published: May 19, 2023 DOI:https://doi.org/10.1016/j.jgo.2023.101506
Darren J. Walsh Kavita Kantilal Chloé Herledan Ginah Nightingale Vanya Slavova-Boneva Maria-Estela Moreno-Martínez Samantha Penn Joey Chien Kumud Kantilal Published: May 19, 2023 DOI :https://doi.org/10.1016/j.jgo.2023.101531
Mariuxi A. Viteri Malone Leana Cabrera Chien Mackenzi Pergolotti Beverly Canin Nicolò Matteo Luca Battisti Jessica L. Krok-Schoen Anahat Kaur Karlynn BrintzenhofeSzoc Elana Plotkin Leigh M. Boehmer Armin Shahrokni Published: May 15, 2023 DOI:https://doi.org/10.1016/j.jgo.2023.101497
Laura M.L. Tielemans Kirsten D. van Heugten Marije E. Hamaker Inez C. van Walree Published: May 15, 2023 DOI:https://doi.org/10.1016/j.jgo.2023.101525
The CLIMB Study Breast cancer remains a significant health concern for older women, who account for appoximately 50% of those diagnosed with the condition. Older patients often have reduced physiological reserve and clinically significant comorbidities, and are more susceptible to both undertreatment and to overtreatment, as well as being more likely to experience treatment toxicity and early discontinuation of therapy. Around 70-80% of breast cancers are categorized as estrogen-receptor (ER) positive. Regardless of the disease stage or setting, a majority of patients diagnosed with ER+ cancers are likely, at some point during their treatment course, to be treated with endocrine therapy (ET), which works to block or prevent estrogen signaling, and is typically taken for between five to ten years in the adjuvant setting. In general, ET comes in one of two forms, either aromatase inhibitors (AI), such as exemestane and letrozole, or selective estrogen receptor modulators (SERMs) such as [...]
Agata Rembielak, Thomas Yau, Baran Akagunduz, Sandrine Aspeslagh, Giuseppe Colloca, Aoife Conway, Falalu Danwata, Veronique del Marmol, Chuck O'Shea, Marthe Verhaert, Rado Zic, Dan Livesey. Published: April 19, 2023 DOI: https://doi.org/10.1016/j.jgo.2023.101502
Pierre Soubeyran, Carine Bellera, Elena Paillaud. Published: April 04, 2023 DOI: https://doi.org/10.1016/j.jgo.2023.101482
Geriatrics PD: Thomas CaprioMed Onc PD: Mohamed TejaniGeriOnc Supporter: Supriya MohileProgram OpportunitiesResearch: at least 1 year, self-funded is preferableClinical: 2-3 years of hematology/oncology fellowship and/or 1 year of geriatricsFunding available: Clinical funding through hematology/oncology and geriatrics fellowshipDuration of program: 3-4 years for clinical fellowship, at least 1 year for researchApplication process: Through ERAS for clinical fellowship, email for research opportunitiesAccepts international trainees: Please inquire with program directorContact person: Fellowship program coordinator – Dina Henchen, Dina_Henchen@URMC.Rochester.eduWebsite
International Society of Geriatric Oncology
P/A Comptabilis
9 route des Jeunes
1227 Les Acacias - Switzerland
In Special Consultative Status with the United Nations Economic and Social Council (ECOSOC).
Powered by K.I.T. Group – Crafted for Excellence
